VSEE HEALTH, INC. — fact timeline

VSEE HEALTH, INC. entered into Stock Purchase Agreement with Go Biz Holdings, LLC valued at Company agreed to purchase $2.0 million of shares of GMRx common stock, representing a ten percent o (effective 2026-01-16).

“On January 16, 2026, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”) with GMRx and Go Biz Holdings, LLC, a Wyoming limited liability company (“GBiz”), pursuant to which the Company agreed to purchase from GBiz $2.0 million of shares of GMRx’s common stock (the “Shares”) in a private transaction pursuant to the exemptions from registration provided in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Rule 506 of Regulation D promulgated thereunder, representing a ten percent (10%) ownership interest in GMRx.”

VSEE HEALTH, INC. entered into Managed Services Agreement with GoMyRx, Inc. valued at Company provides platform administration, customer/user support, third-party vendor coordination, an (effective 2025-12-26).

“On December 26, 2025, VSee Health, Inc., a Delaware Corporation (the “Company”) and iDoc Virtual Telehealth Solutions, Inc., a Texas Corporation and wholly-owned subsidiary of the Company, entered into a Managed Services Agreement with GoMyRx, Inc., a Wyoming corporation (“GMRx”), a digital prescription fulfillment platform and affiliate company of the GoMyDocs healthcare ecosystem (the “MSA”).”

VSEE HEALTH, INC.: Reduced quorum for stockholder meetings to one-third of voting power (effective 2025-12-17).

“On December 17, 2025, the Board of Directors of VSee Health, Inc. (the “Company”) approved an amendment of the Company’s Bylaws to reduce the quorum needed for stockholder meetings to one-third (33.33%) of the voting power of the shares of capital stock of the Company issued and outstanding and entitled to vote at a meeting of stockholders, present in person or represented by proxy.”

VSEE HEALTH, INC.: On December 4, 2025, VSee Health, Inc. filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock with the Delaware Secretary of State, designating 2,000 shares of Series B Preferred Stock with a stated value of $1,000 per share, effective Decem (effective 2025-12-05).

“On December 4, 2025, VSee Health, Inc. (the “Company”) filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the “Series B Certificate of Designations”) with the Secretary of State of the State of Delaware, effective as of December 5, 2025, which provides for the designation of 2,000 shares of Series B Preferred Stock of the Company, par value $0.0001 per share (the “Series B Preferred Stock”), upon the terms and conditions as set forth in the Series B Certificate of Designations.”

VSEE HEALTH, INC. incurred convertible notes of $217,391 with an accredited institutional investor at 18% per annum maturing October 29, 2026.

“On October 29, 2025, VSee Health, Inc. (the "Company"), entered into a convertible note purchase agreement (the "CNPA") with an accredited institutional investor (the "Investor"), whereby the Investor purchased a convertible promissory note in the initial principal amount of $217,391”

VSEE HEALTH, INC. incurred loan of $133,333.33 with an accredited institutional investor at 5% per annum maturing May 20, 2026.

“the Company issued to the Investor a secured note in the aggregate principal amount of $133,333.33 (the “Note”) for a purchase price of $120,000. The Note bears interest at the rate of 5% per annum and matures on May 20, 2026.”

VSEE HEALTH, INC. engaged WWC, P.C. as its auditor.

“On September 18, 2025, following a competitive review process conducted by the Audit Committee of the Board, the Audit Committee approved the engagement of WWC, P.C. (“WWC”) effective immediately as the Company’s new independent registered public accounting firm for the audit of the Company’s financial statements for the fiscal year ending December 31, 2025, and for the review of the interim financial information for the quarters ending March 31, 2025, June 30, 2025 and September 30, 2025.”

VSEE HEALTH, INC. dismissed WithumSmith+Brown, PC as its auditor.

“On September 15, 2025, VSee Health Inc., a Delaware Corporation (the “Company”), and the Company’s board of directors (the “Board”) notified WithumSmith+Brown, PC (“Withum”), the Company’s independent registered public accounting firm, of its decision to dismiss Withum as the Company’s independent registered public accounting firm, effective immediately.”

VSEE HEALTH, INC. incurred debt of $133,333.33 with an accredited institutional investor at 5% per annum maturing May 8, 2026.

“On October 9, 2025, VSee Health, Inc. (the “Company”) entered into a note purchase agreement (the “Note Purchase Agreement”) with an accredited institutional investor (the “Investor”) pursuant to which the Company issued to the Investor a secured note in the aggregate principal amount of $133,333.33 (the “Note”) for a purchase price of $120,000. The Note bears interest at the rate of 5% per annum and matures on May 8, 2026.”

VSEE HEALTH, INC. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“sdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025. The Company is also not currently in compliance with Nasdaq Listing Rule 5550(b)(1) because the Company’s stockholders’ equity had fallen below the $2,500,000 required minimum for continued listing as of December 31, 2024. The Company is working on remedying these deficiencies, but there can be no assurance that the Company will be eligible for the additional 180 calenda”

VSEE HEALTH, INC. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“curities, including its common stock and public warrants, would be subject to delisting. In the event of such a notification, the Company may appeal the Nasdaq staff’s determination to delist its securities. As previously reported, the Company is currently not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025. The Company is also not currently in compliance with Nasdaq Listing Rule 5550(b)(1) because”

VSEE HEALTH, INC. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“September 2, 2025, the Company received an additional notification letter (the “Letter”) from the Staff indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”) because the Company’s stockholders’ equity had fallen below the $2,500,000 required minimum for continued listing. The Company’s stockholders’ deficit was $18,488 as of December 31, 2024, as reported in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 . The Letter also noted that, as of August 29, 2025, the Company did not meet the alternatives of marke”

VSEE HEALTH, INC. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“August 28, 2025 (although as of the filing of this Current Report on Form 8-K, trading has not been suspended) . The Company filed an appeal with the Nasdaq Hearings Panel (the “Panel”), and a hearing before the Panel is scheduled to be held on September 9, 2025. The Staff’s determination to deny the Company’s request to continue listing on Nasdaq was based on the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file with the Securities and Exchange Commission (the “SEC”) its Annual Report on Form 10-K for the fiscal year ended Decembe”

VSEE HEALTH, INC. reported that prior financial statements should not be relied upon.

“On July 17, 2025, management of the Company, in consultation with the Company’s Board of Directors (including the members of the Audit Committee thereof), concluded that the Prior Financial Statements (other than the March 31, 2023 and March 31, 2024 consolidated financial statements of VSee Lab) should no longer be relied upon due to the impact of the errors noted below and will be restated.”

VSEE HEALTH, INC. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“August 20, 2025, the Company received an additional notice from the Staff that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The Company intends to address all late filings before the Panel at the scheduled hearing. While the Company pursues those processes, trading in the Company’s common stock and public warrants will be suspended on Nasdaq after August 28, 2025, unless the Panel grants an additional extension. As a result of the suspension in tradi”

VSEE HEALTH, INC. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“mpany’s filing of an appeal with the Nasdaq Hearings Panel (the “Panel”). A hearing before the Panel is scheduled to be held on September 9, 2025. The Staff’s determination to deny the Company’s request to continue listing on Nasdaq was based on the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file with the Securities and Exchange Commission (the “SEC”) its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the period ended March 31, 2025. On August 20, 2025, the Company”

VSEE HEALTH, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“December 31, 2024 (the “Form 10-K”) with the Securities and Exchange Commission (the “SEC”). As previously reported, on May 23, 2025, the Company received a notice (the “Second Notice” and, together with the First Notice, the “Notices”) from the Staff of Nasdaq that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Form 10-Q”) with the SEC. On August 5, 2025, the Company received a letter from the Staff stating that the Staff had determined to deny the Compan”

David L. Wickersham was appointed as Class III Director at VSEE HEALTH, INC..

“On July 17, 2024, the Board of Directors (the “Board”) of VSee Health, Inc. (the “Company”) voted to increase the size of the Board from five to seven members, and to appoint Cydonii V. Fairfax and David L. Wickersham as new Class III directors to fill the vacancies created by such increase, with such appointments effective July 17, 2024.”

Cydonii V. Fairfax was appointed as Class III Director at VSEE HEALTH, INC..

“On July 17, 2024, the Board of Directors (the “Board”) of VSee Health, Inc. (the “Company”) voted to increase the size of the Board from five to seven members, and to appoint Cydonii V. Fairfax and David L. Wickersham as new Class III directors to fill the vacancies created by such increase, with such appointments effective July 17, 2024.”

Jerry Leonard was appointed as Chief Financial Officer and Secretary at VSEE HEALTH, INC..

“Jerry Leonard was appointed Chief Financial Officer and Secretary of the Company”

Imoigele Aisiku was appointed as Co-Chief Executive Officer at VSEE HEALTH, INC..

“Imoigele Aisiku was appointed Co-Chief Executive Officer of the Company”

Milton Chen was appointed as Co-Chief Executive Officer at VSEE HEALTH, INC..

“Milton Chen was appointed Co-Chief Executive Officer of the Company”

Colin O'Sullivan was appointed as Director at VSEE HEALTH, INC..

“Milton Chen, Imoigele Aisiku, and Colin O’Sullivan were appointed as directors of the Company.”

Imoigele Aisiku was appointed as Director at VSEE HEALTH, INC..

“Milton Chen, Imoigele Aisiku, and Colin O’Sullivan were appointed as directors of the Company.”

Milton Chen was appointed as Director at VSEE HEALTH, INC..

“Milton Chen, Imoigele Aisiku, and Colin O’Sullivan were appointed as directors of the Company.”

George McNellage departed as Director at VSEE HEALTH, INC..

“Scott Wolf, Frank Ciufo, and George McNellage ceased serving on the Board”

Frank Ciufo departed as Director at VSEE HEALTH, INC..

“Scott Wolf, Frank Ciufo, and George McNellage ceased serving on the Board”

Scott Wolf departed as Director at VSEE HEALTH, INC..

“Scott Wolf, Frank Ciufo, and George McNellage ceased serving on the Board”

VSEE HEALTH, INC. amended Extension Letter Agreement with an institutional and accredited investor (effective 2024-04-17).

“On April 17, 2024, the Company and the investor entered into a letter agreement (the “Extension Letter Agreement”), which amended the maturity date of the Extension Note to June 30, 2024 and clarified certain definitions and transaction terms in both the Extension Purchase Agreement and the Extension Note”

VSEE HEALTH, INC. amended Bridge Letter Agreement with the Bridge Investor (effective 2024-04-17).

“On April 17, 2024, the Company, VSee, and iDoc entered into a letter agreement with the Bridge Investor (the “Bridge Letter Agreement”), which amended the date with respect to the termination or closing of the business combination referenced in the Bridge Notes from March 31, 2024 to June 30, 2024”

VSEE HEALTH, INC. amended Second Amendment with Digital Health Acquisition Corp., DHAC Merger Sub I, Inc., DHAC Merger Sub II, Inc., VSee Lab, Inc., iDoc Virtual Telehealth Solutions, Inc. (effective 2024-04-17).

“On April 17, 2024, the Parties entered into a Second Amendment (the “Second Amendment”) to the Business Combination Agreement, pursuant to which the termination date in the Business Combination Agreement was amended from March 31, 2024 to June 30, 2024”

VSEE HEALTH, INC. entered into Third Amended and Restated Business Combination Agreement with Digital Health Acquisition Corp., DHAC Merger Sub I, Inc., DHAC Merger Sub II, Inc., VSee Lab, Inc., iDoc Virtual Telehealth Solutions, Inc. (effective 2023-11-21).

“Digital Health Acquisition Corp. (“DHAC” or the “Company”), DHAC Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of DHAC (“Merger Sub I”), DHAC Merger Sub II, Inc., a Texas corporation and a wholly owned subsidiary of DHAC (“Merger Sub II” and together with Merger Sub I, the “Merger Subs”), VSee Lab, Inc., a Delaware corporation (“VSee”), and iDoc Virtual Telehealth Solutions, Inc., a Texas corporation (“iDoc” and together with DHAC, Merger Sub I, Merger Sub II, VSee and iDoc, the “Parties”), entered into a Third Amended and Restated Business Combination Agreement on November 21, 2023”